An Adjuvanted Vaccine-Induced Pathogenesis Following Influenza Virus Infection

Shiou-Chih Hsu,Kun-Hsien Lin,Yung-Chieh Tseng,Yang-Yu Cheng,Hsiu-Hua Ma,Ying-Chun Chen,Jia-Tsrong Jan,Chung-Yi Wu,Che Ma

DOI: https://doi.org/10.3390/vaccines12060569

2024-05-23

Vaccines

Abstract:An incomplete Freund's adjuvant elicited an overt pathogenesis in vaccinated mice following the intranasal challenge of A/California/07/2009 (H1N1) virus despite the induction of a higher specific antibody titer than other adjuvanted formulations. Aluminum hydroxide adjuvants have not induced any pathogenic signs in a variety of formulations with glycolipids. A glycolipid, α-galactosyl ceramide, improved a stimulatory effect of distinct adjuvanted formulations on an anti-influenza A antibody response. In contrast to α-galactosyl ceramide, its synthetic analogue C34 was antagonistic toward a stimulatory effect of an aluminum hydroxide adjuvant on a specific antibody response. The aluminum hydroxide adjuvant alone could confer complete vaccine-induced protection against mortality as well as morbidity caused by a lethal challenge of the same strain of an influenza A virus. The research results indicated that adjuvants could reshape immune responses either to improve vaccine-induced immunity or to provoke an unexpected pathogenic consequence. On the basis of these observations, this research connotes the prominence to develop a precision adjuvant for innocuous vaccination aimed at generating a protective immunity without aberrant responses.

immunology,medicine, research & experimental

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the impact of different adjuvant formulations on the immune response induced by influenza vaccines. In particular, it studies whether certain glycolipids can enhance the vaccine - induced immunity or trigger abnormal pathological reactions. Specifically, the researchers are concerned with:

1. **Evaluating the impact of different glycolipid adjuvant formulations on vaccine - induced immune responses**: The researchers experimentally evaluated the effects of different glycolipids (such as α - galactosylceramide (α - GC) and its synthetic analogue C34) in Freund's incomplete adjuvant (IFA) and aluminum hydroxide adjuvant (AH) to determine whether they can enhance the immunogenicity of the vaccine.

2. **Investigating whether certain glycolipids may trigger abnormal pathological reactions**: The study found that certain adjuvant formulations (such as those containing α - GC) can significantly increase the level of vaccine - induced specific antibodies, while other formulations (such as those containing C34) may have an inhibitory effect on the antibody response. In addition, the study also observed that vaccines using certain adjuvant formulations (such as IFA) may lead to obvious pathological reactions, such as weight loss and behavioral changes, after influenza virus challenge.

3. **Developing safer and more effective adjuvant formulations**: Based on the above findings, the researchers aim to develop a precise adjuvant formulation that can effectively enhance the protective effect of the vaccine without causing abnormal pathological reactions. In particular, the study shows that when aluminum hydroxide adjuvant (AH) is used alone, it can provide complete protection against death and disease caused by a lethal dose of influenza virus challenge.

Overall, the goal of this study is to provide a scientific basis for future vaccine development through a systematic evaluation of the effects of different adjuvant formulations, especially in the development of influenza vaccines, to find adjuvant formulations that can enhance the immune response without causing adverse side effects.